This approach enables dynamic monitoring of IFN-γ-producing tumour-reactive CD4+ T cells using an ELISpot assay, regardless of HLA type.22–26 Around 35% of therapy-naive NSCLC patients harboured circulating anti-TERT Th1. This evidence concerns the gene CD4 and neoplasm.